Business
Movano Inc. Provides Business Update and Reports Second Quarter 2021 Financial Results
Conference call begins at 2:00 p.m. Pacific time todayPLEASANTON, CA / ACCESSWIRE / August 12, 2021 / Today, Movano Inc. (NASDAQ:MOVE), a health technology
About this update from Corvex, Inc.
[{"type":"text","content":"Conference call begins at 2:00 p.m. Pacific time todayPLEASANTON, CA / ACCESSWIRE / August 12, 2021 / Today, Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to help prevent and better manage chronic diseases, reported financial results for the three months ending June 30, 2021 and provided a business update. Highlights from the second quarter and recent weeks include the following:During the second quarter 2021, the Company received approval from the Institutional Review Board (IRB) to conduct blood pressure studies with up to 200 participants at the Movano Clinical Lab, located in its corporate office space. In late-June 2021, the Company used its noninvasive, iPhone-sized prototype to collect pulse pressure waveform data from 45 external volunteers with varying gender, age, weight, ethnicity and blood pressure. During each session, participants wore Movano's prototype along with a hospital-grade FDA-cleared vital signs monitor as the control. The Company expects to use this data to further evaluate key modeling factors and continue to improve upon blood pressure algorithm development. The study marked an important milestone for Movano as it confirmed the Company's ability to efficiently enroll subjects and conduct testing in its own space, enabling Movano's Clinical team to have more opportunities to collect data as needed in the future.Movano announced today that its wearable device prototype could be operational and out of the development stage by the end of the third quarter or early fourth quarter 2021 and ready for an upcoming clinical study shortly thereafter, both of which would be significant milestones and steps forward in productizing the Company's technology. With this smaller, wrist-worn device, Movano will be transitioning from an iPhone-sized, tethered prototype to the first iteration of its completely wireless, battery powered wearable device. The new device is expected to advance testing capabilities, improve the quality and quantity of data collected, and enable Movano's Clinical team to conduct longer and more complex studies. Movano plans to conduct a blood pressure study in the fourth quarter, under an approved IRB protocol, using the new wearable device.During the second quarter 2021, Movano continued to progress with the m...